| 兰芝荟,闫丰元.Avelumab治疗罕见Merkel细胞癌的作用机制及安全性研究[J].中国药事,2018,32(5):620-623 |
| Avelumab治疗罕见Merkel细胞癌的作用机制及安全性研究 |
| Mechanism of Action and Safety Evaluation of Avelumab for the Treatment of Rare Merkel Cell Carcinoma |
| 投稿时间：2017-05-31 |
| DOI：10.16153/j.1002-7777.2018.05.008 |
| 中文关键词: BAVENCIO注射液 单克隆抗体 Merkel细胞癌 程序性死亡受体-配体1 |
| 英文关键词: avelumab monoclonal antibody merkel cell carcinoma programmed death-ligand 1(PD-L1) |
| 基金项目: |
|
| 摘要点击次数: 1163 |
| 全文下载次数: 779 |
| 中文摘要: |
| Merkel细胞癌（MCC）是一种罕见的、起源于神经内分泌细胞的具有侵袭性的皮肤恶性肿瘤。Avelumab是一种人源化的IgG1单克隆抗体，通过阻断程序性死亡受体-配体1（PD-L1）的活性抑制肿瘤生长。Avelumab是获准用于治疗转移性Merkel细胞癌（MCC）的药物。本文就avelumab的作用机制、临床研究及药物安全性等方面进行简述，为临床使用提供参考。 |
| 英文摘要: |
| Merkel cell carcinoma (MCC) is a rare and invasive skin malignant tumor originated from neuroendocrine cells. Avelumab is a humanized IgG1 monoclonal antibody, inhibiting tumor growth by blocking the activity of programmeddeath-ligand 1 (PD-L1) and was frstly approved for the treatment of metastatic MCC by U. S. Food and Drug Administration in March, 2017. In this paper, mechanism of action, clinical study, and drug safety evaluation were described in order to provide references for the clinical use. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |